With $35 Million B Round, Trevena to Push GPCR-Targeted Program into Phase II for Acute Heart Failure

Four investors returned to back the Duke University spinout, which is developing biased ligand small molecules.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet